↓ Skip to main content

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

Overview of attention for article published in BMC Cancer, May 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)

Mentioned by

patent
3 patents

Citations

dimensions_citation
193 Dimensions

Readers on

mendeley
123 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
Published in
BMC Cancer, May 2012
DOI 10.1186/1471-2407-12-199
Pubmed ID
Authors

Peter J Hosein, Jessica Macintyre, Carolina Kawamura, Jennifer Cudris Maldonado, Vinicius Ernani, Arturo Loaiza-Bonilla, Govindarajan Narayanan, Afonso Ribeiro, Lorraine Portelance, Jaime R Merchan, Joe U Levi, Caio M Rocha-Lima

Abstract

5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) is superior to gemcitabine in patients with metastatic pancreatic cancer who have a good performance status. We investigated this combination as neoadjuvant therapy for locally advanced pancreatic cancer (LAPC).

Mendeley readers

The data shown below were compiled from readership statistics for 123 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 2%
Netherlands 1 <1%
France 1 <1%
Unknown 118 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 21 17%
Student > Ph. D. Student 16 13%
Student > Bachelor 14 11%
Other 13 11%
Student > Postgraduate 10 8%
Other 36 29%
Unknown 13 11%
Readers by discipline Count As %
Medicine and Dentistry 80 65%
Biochemistry, Genetics and Molecular Biology 4 3%
Nursing and Health Professions 4 3%
Agricultural and Biological Sciences 3 2%
Pharmacology, Toxicology and Pharmaceutical Science 2 2%
Other 8 7%
Unknown 22 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2022.
All research outputs
#3,031,608
of 21,446,675 outputs
Outputs from BMC Cancer
#709
of 7,748 outputs
Outputs of similar age
#19,613
of 143,264 outputs
Outputs of similar age from BMC Cancer
#1
of 1 outputs
Altmetric has tracked 21,446,675 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,748 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 143,264 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them